ArticleLipids in health and disease2017

Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study.

Parth Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.